Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Epidarex Capital is a transatlantic venture capital firm founded to invest in early-stage, high-growth life science and health technology companies. Established in both Bethesda, Maryland, USA, and Edinburgh, Scotland, the firm focuses on building companies in emerging and under-ventured research hubs within the UK and US. Epidarex leverages its scientific and industry networks to create value and support the development of innovative healthcare solutions.
The firm has a strong presence in both North America and Europe, collaborating with leading universities and research institutions to identify transformative investments. Epidarex Capital has recently closed Fund IV, securing $145 million to support the next wave of life science start-ups, indicating a robust financial backing for future investments. The firm has a diverse portfolio that includes several notable companies, showcasing its commitment to advancing healthcare technologies.
Epidarex Capital invests in early-stage life science opportunities, particularly in biotechnology, pharmaceuticals, medical devices, and health technology. The firm typically provides seed or Series A funding to spin out innovations from leading medical research universities and institutions. Their investment strategy emphasizes transformative technologies that address significant unmet medical needs, focusing on disruptive platform technologies, robust intellectual property, and early traction from key opinion leaders.
Targeting emerging research hubs in the US and UK, Epidarex collaborates closely with academic institutions to identify and develop promising innovations. The firm seeks to partner with scientists and entrepreneurs who are developing groundbreaking products for the global healthcare market. Key evaluation criteria include sustainable competitive advantages and the potential for significant impact in the healthcare sector.
Epidarex Capital has a diverse portfolio of notable companies, including:
A. Sinclair Dunlop - Managing Partner. A seasoned venture capitalist with extensive experience in life sciences, Dunlop has led numerous successful investments in the biotech sector.
Kyparissia Sirinakis - Managing Partner. Sirinakis brings a strong background in healthcare investments and has played a key role in building Epidarex's portfolio.
Elizabeth Roper, Ph.D. - Managing Partner. Roper has a Ph.D. in a relevant scientific field and has significant experience in identifying and developing life science innovations.
Peter Finan, Ph.D. - Managing Partner. Finan's expertise lies in medical devices and pharmaceuticals, contributing to Epidarex's strategic investment decisions.
Mary Canning, Ph.D. - Partner. Canning has a strong background in biotech and has been instrumental in supporting portfolio companies.
Lori Krim Gough, Ph.D. - Partner. Gough specializes in early-stage investments and has a deep understanding of the life sciences market.
Henning Steinhagen, Ph.D. - Venture Partner. Steinhagen brings a wealth of scientific knowledge and industry connections to the firm.
Anthony Voveris - Vice President of Finance. Voveris oversees financial operations and supports investment strategies.
Matthew Miessau - Principal. Miessau focuses on sourcing and evaluating new investment opportunities.
Victor Pong, Ph.D. - Associate. Pong assists in due diligence and portfolio management.
Melissa Lezameta, Ph.D. - Associate. Lezameta contributes to research and analysis of potential investments.
Bridget Harris - Director of Operations. Harris manages the firm's operational functions and supports the team.
Alvin Lewis - Staff Accountant. Lewis handles financial reporting and compliance.
Megan MacDougall - Executive Assistant. MacDougall provides administrative support to the team.
To pitch Epidarex Capital, founders should send an email to info@epidarex.com. The pitch deck should include a comprehensive overview of the business, the technology, market analysis, and the team. Founders can expect a response within a few weeks, depending on the volume of inquiries. Warm introductions are preferred but not mandatory.
Epidarex Capital has established **Epidarex Exeed**, a therapeutic discovery engine aimed at advancing early-stage life science assets. Exeed focuses on transforming breakthrough innovations into investable assets over a 12-18 month period. This program is designed to support startups in navigating the complexities of bringing their innovations to market.
In recent months, Epidarex Capital has been active in announcing significant developments within its portfolio. Notable updates include Lario Therapeutics receiving $2.4 million from The Michael J. Fox Foundation to advance its research in neurological disorders. Additionally, Harness Therapeutics has nominated a first-in-class drug candidate for Huntington’s Disease, marking a significant milestone in its development pipeline.
Furthermore, Epidarex Capital announced the first close of Fund IV, securing $145 million to support the next wave of life science start-ups. This funding will enable the firm to continue its mission of investing in transformative life science innovations across North America and Europe.
What are Epidarex Capital's investment criteria?
Epidarex Capital focuses on early-stage life science opportunities, particularly in biotechnology, pharmaceuticals, medical devices, and health technology. They look for disruptive technologies that address unmet medical needs, sustainable competitive advantages, and robust intellectual property.
How can I pitch to Epidarex Capital?
Founders can pitch Epidarex Capital by sending an email to info@epidarex.com. It is advisable to include a detailed overview of the business, the technology, and the market opportunity in the pitch deck.
What makes Epidarex Capital different from other VCs?
Epidarex Capital distinguishes itself through its strong connections with academic institutions and its focus on transformative life science innovations. The firm actively collaborates with leading universities to identify and develop promising technologies.
What is the geographic scope of Epidarex Capital's investments?
The firm invests primarily in North America and Europe, targeting emerging research hubs in these regions.
What is the typical check size for investments?
Epidarex Capital typically provides seed or Series A funding, although specific check sizes may vary based on the opportunity and stage of the company.
What kind of support does Epidarex Capital provide post-investment?
The firm offers operational support, strategic guidance, and access to its extensive network of industry contacts to help portfolio companies succeed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.